Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients-Reference-Cited by-同舟云学术

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Published:2016-05-11 Issue:6 Volume:107 Page:755-763
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tamura Kenji¹²,Mukai Hirofumi³,Naito Yoichi¹³,Yonemori Kan²,Kodaira Makoto²,Tanabe Yuko¹,Yamamoto Noboru¹⁴,Osera Shozo⁵,Sasaki Masaoki³,Mori Yuko⁶,Hashigaki Satoshi⁶,Nagasawa Takashi⁶,Umeyama Yoshiko⁶,Yoshino Takayuki⁷

Affiliation:

1. Department of Experimental Therapeutics Exploratory Oncology Research and Clinical Trial Center National Cancer Center Tokyo Japan

2. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

3. Department of Breast and Medical Oncology National Cancer Center Hospital East Chiba Japan

4. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

5. Department of Gastroenterology Endoscopy National Cancer Center Hospital East Chiba Japan

6. Pfizer Japan Inc. Tokyo Japan

7. Department of Gastrointestinal Oncology National Cancer Center Hospital East Chiba Japan

Funder

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12932

Reference11 articles.

1. Specific inhibition of cyclin‐dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts;Fry DW;Mol Cancer Ther,2004

2. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

3. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity

4. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells

5. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer;International Immunopharmacology;2024-12

2. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells;Cancer Immunology, Immunotherapy;2024-05-02

3. New Enhancement Spectrofluorimetric Determination of Anti‐Breast Cancer Drugs Palbociclib by Biogenic‐Synthesized Alumina/NiO Nanocomposite;ChemistrySelect;2024-03-07

4. Dispersive liquid-liquid microextraction followed by sweeping micellar electrokinetic chromatography-tandem mass spectrometry for determination of six breast cancer drugs in human plasma;Journal of Chromatography A;2024-03

5. High-throughput screening for Cushing’s disease: therapeutic potential of thiostrepton via cell cycle regulation;2024-02-26